54f37e36ee
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
Pentagon-Agent: Vida <HEADLESS>
64 lines
4.5 KiB
Markdown
64 lines
4.5 KiB
Markdown
---
|
|
type: source
|
|
title: "Omada Health Enhanced GLP-1 Care Track: Persistence, Weight Loss, and Post-Discontinuation Outcomes"
|
|
author: "Omada Health (internal analysis)"
|
|
url: https://www.omadahealth.com
|
|
date: 2025-01-01
|
|
domain: health
|
|
secondary_domains: []
|
|
format: report
|
|
status: unprocessed
|
|
priority: high
|
|
tags: [glp1, adherence, behavioral-wraparound, post-discontinuation, weight-loss, continuous-delivery]
|
|
---
|
|
|
|
## Content
|
|
|
|
Omada Health's Enhanced GLP-1 Care Track analysis (n=1,124 members without diabetes who self-reported GLP-1 use, confirmed via pharmacy claims):
|
|
|
|
**Persistence outcomes:**
|
|
- 94% at 12 weeks (vs. 42-80% industry range)
|
|
- 84% at 24 weeks (vs. 33-74% industry range)
|
|
|
|
**Weight loss outcomes:**
|
|
- Persisters through 24 weeks: 12.1% body weight loss vs. 7.4% for discontinuers (64% relative increase)
|
|
- 12-month persisters: 18.4% average weight loss vs. 11.9% in real-world evidence comparators
|
|
- 28% greater average weight loss vs. matched non-Care Track members
|
|
|
|
**Post-discontinuation outcomes (most significant finding):**
|
|
- 63% of Omada members maintained or continued losing weight 12 months after stopping GLP-1s
|
|
- Average weight change post-discontinuation: 0.8% (near-zero)
|
|
- This is the strongest post-discontinuation data of any commercial program found
|
|
|
|
**Program components:** High-touch care team, dose titration education, side effect management, nutrition guidance, exercise specialist support for muscle preservation, access barrier navigation.
|
|
|
|
**Methodological caveats:**
|
|
- Internal analysis (not peer-reviewed RCT)
|
|
- Survivorship bias: sample includes only patients who remained in Omada after stopping GLP-1s — not population-representative
|
|
- Self-reported GLP-1 use (though confirmed via pharmacy claims)
|
|
- No randomized control condition
|
|
|
|
## Agent Notes
|
|
**Why this matters:** This is the only data I've found suggesting that behavioral wraparound can produce durable weight maintenance AFTER GLP-1 cessation. The prevailing finding across Sessions 20-22 is that GLP-1 benefits revert within 1-2 years of cessation (continuous delivery required). If Omada's post-discontinuation finding holds in peer-reviewed replication, it would scope-qualify the continuous-delivery thesis: GLP-1s without behavioral infrastructure require continuous delivery; GLP-1s WITH comprehensive behavioral wraparound may produce durable changes.
|
|
|
|
**What surprised me:** 63% maintaining or continuing weight loss 12 months post-GLP-1 cessation. I expected near-universal rebound based on STEP 4 trial and other cessation data. The 0.8% average weight change is dramatically better than the ~6-7% average weight regain seen in unassisted cessation. This is a genuine data surprise.
|
|
|
|
**What I expected but didn't find:** Peer-reviewed publication of this finding. The data was apparently presented at ObesityWeek 2025 but a peer-reviewed paper has not been published as of April 2026.
|
|
|
|
**KB connections:**
|
|
- Directly challenges the "continuous delivery required" thesis being developed from Sessions 20-22
|
|
- Relates to: GLP-1 rebound cessation data (STEP 4 trial pattern)
|
|
- Relates to: food-as-medicine reversion claims from Session 17
|
|
- Relates to: antidepressant relapse patterns from Session 21
|
|
|
|
**Extraction hints:**
|
|
- Primary claim candidate: "Comprehensive behavioral wraparound may enable durable weight maintenance post-GLP-1 cessation, challenging the unconditional continuous-delivery requirement" — but ONLY if the extractor notes the methodological limits (observational, survivorship bias, not peer-reviewed)
|
|
- Secondary claim: "Industry-wide GLP-1 persistence at 12 weeks ranges from 42-80% without wraparound programs; programs with high-touch behavioral support report 84-94% — a 20-40 percentage point improvement"
|
|
- Confidence: should be rated EXPERIMENTAL until peer-reviewed replication exists
|
|
|
|
**Context:** Omada Health is a digital health company with employer-sponsored programs. They have financial incentives to show strong outcomes. The finding is potentially transformative but requires independent replication.
|
|
|
|
## Curator Notes (structured handoff for extractor)
|
|
PRIMARY CONNECTION: Claims about continuous-delivery requirement for GLP-1 effects (being drafted from Sessions 20-22 patterns)
|
|
WHY ARCHIVED: Most significant post-discontinuation data found; directly challenges the categorical "continuous delivery required" claim and demands scope qualification
|
|
EXTRACTION HINT: Extract the finding with EXPERIMENTAL confidence and explicit scope — "with comprehensive behavioral wraparound" not "with any GLP-1 program"; flag for divergence consideration against GLP-1 rebound cessation data
|